Hematocrit Test Devices Market – By Product, By Modality, By Application, By End Use - Global Forecast, 2025 to 2034

Hematocrit Test Devices Market Size

The global hematocrit test devices market size was valued at USD 3.8 billion in 2024 and is expected to exhibit growth at a CAGR of 4.4% from 2025 to 2034 period. The high market growth can be attributed to the increasing prevalence of blood disorders, growing geriatric population, and advancements in point-of-care testing, among other contributing factors.
 

Moreover, the rising prevalence of blood disorders including anemia, polycythemia, and sickle cell disease increases the demand for hematocrit testing. For instance, according to the World Health Organization (WHO), anemia affects about 1.62 billion people globally, representing 24.8% of the population. Similarly, the Centers for Disease Control and Prevention (CDC) reports that sickle cell disease affects approximately 100,000 Americans, with 1 in 365 Black or African American births having the condition. Hence, these medical conditions require continuous monitoring of hematocrit levels, which drives the need for accurate and accessible testing equipment.
 

Hematocrit test devices are diagnostic tools used to measure the proportion of red blood cells (RBCs) in a person blood. This test is essential for diagnosing various conditions such as anemia, dehydration, and polycythemia. These devices typically provide rapid, accurate results by analyzing blood samples, and they come in various forms, including analyzers, meters, and point-of-care testing devices.
 

Hematocrit Test Devices Market Trends

The market is witnessing significant growth driven by advancements in non-invasive testing, surging need for integrated wearable health technology, and increased adoption of home care testing, among other factors are boosting the industry growth.
 

• Further, there is a growing trend toward miniaturizing hematocrit testing devices, making them more portable and user-friendly. These compact devices allow for easier transport and use in various settings, including remote locations, fieldwork, and by non-specialized healthcare personnel.
   
• Additionally, more hematocrit test devices are integrating with electronic health records (EHR) systems, allowing for seamless data sharing between healthcare providers. This trend enhances the continuity of care, streamlines patient management, and facilitates data-driven decision-making, thereby aforementioned factors are expected to drive the market.
   

Hematocrit Test Devices Market Analysis

Based on product, the market is classified into instruments, reagents and consumables. The instruments segment is further bifurcated into hematocrit test analyzer and hematocrit test meter. The instruments segment generated the highest revenue of USD 2.2 billion in 2024.
 

• The increasing incidence of blood-related conditions, such as anemia, polycythemia, and other hematological disorders, creates a consistent demand for reliable hematocrit testing. Hematocrit test analyzers and meters are essential for the regular monitoring of blood cell concentrations, driving demand in clinical and diagnostic settings.
   
• Furthermore, continuous technological advancements have led to more accurate, reliable, and faster hematocrit testing. These innovations in hematocrit analyzers and meters enhance diagnostic precision, making them more appealing to healthcare professionals for clinical use, which further strengthens the market dominance of this segment.
   

Based on modality, the hematocrit test devices market is classified into laboratory-based testing and point-of-care (POC) testing. The laboratory-based testing segment accounted for USD 2.5 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 4.2% between 2025 to 2034 period.
 

• Laboratory-based hematocrit testing devices are known for their high precision and reliability in providing accurate results. Healthcare professionals rely on these tests to diagnose conditions such as anemia, polycythemia, and dehydration, where precise hematocrit levels are essential for treatment planning.
   
• Additionally, as the complexity of health conditions increases and the demand for detailed diagnostic testing grows, laboratory-based testing remains the gold standard for hematocrit analysis. Healthcare providers require highly accurate data for more complex patient profiles, which can be achieved through lab-based instruments. This is expected to drive growth in this segment of the market.
   

Based on application, the hematocrit test devices market is classified into anemia, congenital heart diseases, polycythemia vera, and other applications. The anemia segment dominated the market in 2024 with a market share of 45.8%.
 

• Anemia, especially iron-deficiency anemia, is one of the most common blood disorders globally, particularly affecting women, children, and the elderly. The high number of anemia cases increases the demand for reliable and accurate hematocrit testing to monitor and diagnose the condition.
   
• Further, the growing awareness about anemia and its impact on health has led to more regular screenings. Early detection through hematocrit tests helps in timely intervention and treatment, reducing complications associated with anemia. This drives the need for hematocrit test devices in clinical and point-of-care settings. This is anticipated to boost the segmental growth in the market.

Based on end use, the hematocrit test devices market is segmented into hospitals, diagnostic laboratories, ambulatory surgical centers, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 3 billion by the end of the forecast period.
 

• Hospitals require accurate and reliable testing devices to diagnose and manage a variety of blood disorders, including anemia, dehydration, and polycythemia. Hematocrit tests are integral for diagnosing these conditions and informing treatment plans, driving the demand for advanced hematocrit test devices in hospital settings.
   
• Moreover, the increasing number of hospital patients with chronic conditions like cardiovascular disease, kidney disease, and diabetes, which often result in anemia or other blood abnormalities, is fueling the need for regular hematocrit testing. Hospitals need efficient and precise hematocrit devices to monitor and manage these conditions.

U.S. hematocrit test devices market accounted for USD 1.4 billion market revenue in 2024 and is anticipated to grow at a CAGR of 3.9% between 2025 to 2034 period.
 

• The U.S. has a significant population suffering from various blood disorders, such as anemia, polycythemia, and sickle cell disease. This high prevalence of conditions that require regular hematocrit monitoring drives the demand for reliable and accurate hematocrit test devices in both clinical and home healthcare settings.
   
• Additionally, the country boasts one of the most advanced healthcare infrastructures in the world, with state-of-the-art diagnostic tools widely available. The continuous adoption of cutting-edge hematocrit test devices in hospitals, clinics, and diagnostic laboratories is a key driver, as these devices are essential for accurate diagnostics and patient management.
   

Germany hematocrit test devices market is projected to grow remarkably in the coming years.
 

• Germany has a well-established and advanced healthcare system with state-of-the-art diagnostic facilities. The widespread availability of hematocrit test devices in hospitals, clinics, and diagnostic centers supports the accurate and efficient diagnosis of conditions like anemia, making country a key market for hematocrit testing devices.
   
• Favorable government policies, including healthcare reimbursement for diagnostic procedures, encourage the use of hematocrit test devices. Financial support for patients undergoing regular testing makes these devices more accessible, fostering market growth in Germany.
   

Japan holds a dominant position in the Asia Pacific hematocrit test devices market.
 

• Japan has one of the oldest populations in the world, with a significant proportion of the population over 65 years old. As older individuals are more prone to chronic diseases such as anemia, cardiovascular disease, and kidney disorders, there is an increasing demand for regular hematocrit testing to monitor these conditions, driving growth in the market.
   
• Moreover, the Japanese government strongly supports preventive healthcare through national health programs and screenings. Regular health check-ups, which often include blood tests for anemia and other conditions, are common in Japan. This focus on preventive care leads to increased demand for accurate hematocrit test devices in both clinical and point-of-care settings.
   

Hematocrit Test Devices Market Share

The market is highly competitive, with key players including Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Pointe Scientific. These companies offer a range of hematocrit testing solutions, including automated analyzers, portable meters, and point-of-care devices. Innovation in technology, such as improved accuracy, faster results, and integration with healthcare IT systems, is a key competitive factor. Strategic collaborations, mergers, and acquisitions, along with investments in research and development, are common tactics used by these players to expand their market share.
 

Hematocrit Test Devices Market Companies

Prominent players operating in the hematocrit test devices industry include:

• MENARINI Group
• Abbott
• BIO-RAD
• Boule
• Danaher
• Diatron
• EKF
• Roche
• HORIBA Medical
• Mindray
• NIHON KOHDEN
• Nova Biomedical
• SENSA CORE
• SIEMENS Healthineers
• Sysmex
   

Hematocrit Test Devices Industry News:

• In July 2024, EKF Diagnostics announced the launch of its new Biosen C-Line, an advanced version of its industry-leading rapid hematocrit analyzer. It was designed to enhance usability with a new color touch screen and advanced connectivity, enabling seamless integration with hospital and laboratory IT systems. This innovation ensures quick and secure availability of patient results to clinicians. With this launch, the company strengthened its position in the hematocrit testing market, offering improved workflow efficiency and attracting healthcare facilities seeking advanced, connected solutions for enhanced patient care.
   

The hematocrit test devices market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
  • Hematocrit test analyzer
  • Hematocrit test meter
• Reagents and consumables

Market, By Modality

• Laboratory-based testing
• Point-of-care (POC) testing

Market, By Application

• Anemia
• Congenital heart diseases
• Polycythemia vera
• Other applications

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE